ACRF Cancer Genomics Facility
ACRF Cancer Genomics Facility

ACRF Cancer Genomics Facility

Over the last 10 years, technological developments have greatly accelerated our understanding of genetics and genomics of inherited diseases and cancer. Advancements in microarray, microfluidics and next-generation sequencing technologies have ushered in a new era of genomics research and the prospect of genomics-based personalised medicine.

The Australian Cancer Research Foundation (ACRF) Cancer Genomics Facility offers the research community the full benefit of the expertise and technology available at the Centre for Cancer Biology. We provide a full range of state-of-the-art genomics and bioinformatics services to South Australian researchers. 

Opened in October 2012, underpinned by grants totalling more than $6 million, we are equipped with the latest instrumentation for next-gen sequencing, including:

  • Sanger sequencing
  • Next generation sequencing from Illumina, Ion Torrent and Roche
  • Sequenom MassArrays
  • Microarrays from Affymetrix and Illumina
  • Fluidigm equipment for the study of single cells
  • A number of other validation methods and sample preparation robotics

Importantly, in collaboration with eResearch SA, South Australia’s high performance computing node, we have started to build our in-house capability to analyse and interpret the vast amounts of data generated by these new technologies. This includes not only ‘super’-computer infrastructure, but also people skilled in analysing and interpreting this data.

See full equipment listing.

Partnerships and funding

Dynamic partnerships and collaborations have made an enormous contribution to the development of our cutting edge facility. The Cancer Genomics Facility is an AIB supported laboratory, is run in partnership with SA Pathology  and the University of Adelaide, and is developing analytical capacity in collaboration with eResearch SA.

The significant funding the Cancer Genomics Facility has attracted is a reflection of our great value to the research community, and to the wider community. We have received a $3.5 million grant from the Australian Cancer Research Foundation, a State Government contribution of a further $1.05 million, $525,000 from the Cancer Council SA, $1.4 million from Therapeutic Innovation Australia, and $400,000 from the CRC for Biomarker Translation.